Focal Therapy Posts 0.1% 10-Year Prostate Cancer Death Rate as New Data Deepens Debate
Updated
Updated · STAT · Aug 21
Focal Therapy Posts 0.1% 10-Year Prostate Cancer Death Rate as New Data Deepens Debate
1 articles · Updated · STAT · Aug 21
Summary
A U.K. study reported just 0.1% of focal-therapy patients had died of prostate cancer after 10 years, with higher satisfaction and fewer side effects than standard treatment.
That evidence is sharpening a split among urologists because the American Urological Association still classifies focal therapy as experimental and says it should be used only in studies or registries.
A JAMA paper found 51% of focal-therapy use fell outside guideline-supported intermediate-risk cases, including low-risk patients who would usually be monitored with active surveillance.
U.S. uptake remains limited at 1.3% of prostate cancer patients, even as the one-session treatment appeals to men trying to avoid incontinence and erectile dysfunction tied to surgery or radiation.
The broader dispute now centers on whether quality-of-life gains are enough without randomized head-to-head trials showing focal therapy matches surgery or radiation on long-term cancer control.